Beyond mecA: a two-tiered mechanism and regulatory rewiring drive high-level ceftaroline resistance in clinical MRSA

Document Type

Article

Publication Date

1-7-2026

Institution/Department

Center for Molecular Medicine

Journal Title

Antimicrobial agents and chemotherapy

Abstract

High-level resistance to ceftaroline, a fifth-generation β-lactam critical for treating methicillin-resistant Staphylococcus aureus (MRSA), is an emerging threat to global health. While resistance is traditionally attributed to mecA-mediated expression of PBP2a, our study reveals a previously unrecognized mechanism. We show that high-level resistance to ceftaroline can arise independently of ceftaroline exposure through a collateral pathway triggered by carbapenems typically used to treat Gram-negative infections. Our findings reveal a two-tiered adaptive process. First, meropenem selects non-synonymous mutations in rpoB, a core transcriptional regulator, which primes resistance by reprogramming gene expression. These changes consistently co-occur with a key substitution in pbp1 (H499R), an essential protein for cell division, and specific mecA variants (Y446H, E447K) following ceftaroline exposure. Second, resistance is stabilized through regulatory and signaling adaptations, with elevated basal levels of the oxidative stress regulator Spx and its adaptor protein TrfA supporting the altered cellular state. Proteomic and biophysical studies revealed direct binding of TrfA to GdpP, the phosphodiesterase for cyclic-di-AMP, linking this regulatory circuit to elevated c-di-AMP levels and resistance maintenance. Our findings challenge the assumption that ceftaroline resistance is driven solely by PBP2a alterations and reveal how collateral resistance pathways can be activated by broad-spectrum antibiotic use. This study highlights the evolutionary capacity of MRSA to circumvent antibiotic pressure and underscores the need for improved antimicrobial stewardship.

First Page

e0058625

Link to Full Text

Share

COinS